![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAM72B |
Gene summary for FAM72B |
![]() |
Gene information | Species | Human | Gene symbol | FAM72B | Gene ID | 653820 |
Gene name | family with sequence similarity 72 member B | |
Gene Alias | p17 | |
Cytomap | 1p11.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q86X60 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
653820 | FAM72B | P4T-E | Human | Esophagus | ESCC | 2.20e-02 | 1.02e-01 | 0.1323 |
653820 | FAM72B | P5T-E | Human | Esophagus | ESCC | 3.50e-02 | 8.68e-02 | 0.1327 |
653820 | FAM72B | P24T-E | Human | Esophagus | ESCC | 3.52e-19 | 7.62e-01 | 0.1287 |
653820 | FAM72B | P32T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.11e-01 | 0.1666 |
653820 | FAM72B | P52T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.02e-01 | 0.1555 |
653820 | FAM72B | P75T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.30e-01 | 0.1125 |
653820 | FAM72B | P83T-E | Human | Esophagus | ESCC | 8.77e-03 | 1.37e-01 | 0.1738 |
653820 | FAM72B | P91T-E | Human | Esophagus | ESCC | 5.34e-06 | 5.50e-01 | 0.1828 |
653820 | FAM72B | P130T-E | Human | Esophagus | ESCC | 1.66e-02 | 1.22e-01 | 0.1676 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM72B | SNV | Missense_Mutation | novel | c.362N>G | p.Asn121Ser | p.N121S | Q86X60 | protein_coding | tolerated(0.19) | possibly_damaging(0.554) | TCGA-AR-A5QQ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
FAM72B | SNV | Missense_Mutation | novel | c.331N>A | p.Asp111Asn | p.D111N | Q86X60 | protein_coding | tolerated(0.15) | benign(0.013) | TCGA-VS-A9UR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
FAM72B | SNV | Missense_Mutation | novel | c.60C>A | p.Phe20Leu | p.F20L | Q86X60 | protein_coding | deleterious(0.05) | possibly_damaging(0.63) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FAM72B | SNV | Missense_Mutation | novel | c.350C>T | p.Ser117Phe | p.S117F | Q86X60 | protein_coding | tolerated(0.06) | benign(0.281) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
FAM72B | SNV | Missense_Mutation | c.284N>T | p.Ser95Phe | p.S95F | Q86X60 | protein_coding | deleterious(0) | possibly_damaging(0.891) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM72B | SNV | Missense_Mutation | novel | c.446G>T | p.Arg149Ile | p.R149I | Q86X60 | protein_coding | deleterious(0) | possibly_damaging(0.718) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
FAM72B | SNV | Missense_Mutation | c.161A>G | p.Asp54Gly | p.D54G | Q86X60 | protein_coding | tolerated(0.19) | probably_damaging(0.917) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
FAM72B | SNV | Missense_Mutation | novel | c.41N>T | p.Ser14Phe | p.S14F | Q86X60 | protein_coding | tolerated(0.7) | benign(0.392) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAM72B | SNV | Missense_Mutation | novel | c.95C>T | p.Ala32Val | p.A32V | Q86X60 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
FAM72B | SNV | Missense_Mutation | novel | c.355N>A | p.Gly119Ser | p.G119S | Q86X60 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-BR-7704-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |